Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo

Biotechnology Journal

Volumn 9, Issue 9, 2014, Pages 1115-1128

  Hickman, John A ^a   Graeser, Ralph ^b   de Hoogt, Ronald ^b   Vidic, Suzana ^b   Brito, Catarina ^c,d   Gutekunst, Matthias ^e   van der Kuip, Heiko ^e   Imi Predect consortium, ^a  

^a IMI PREDECT   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^d INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

3D models; Bioreactors; Cancer; Drug discovery; Tissue slices

Indexed keywords

BIOREACTORS; CYTOLOGY; DRUG PRODUCTS; TUMORS;

3D MODELS; CANCER; DRUG DISCOVERY; IMPORTANT FEATURES; INNOVATIVE MODELS; STIRRED BIOREACTORS; THREE-DIMENSIONAL MODEL; TISSUE SLICE; CANCER CELLS; IN-VITRO;

DISEASES; BIOREACTORS;

ANIMAL; BIOLOGICAL MODEL; BIOREACTOR; CULTURE TECHNIQUE; CYTOLOGY; HUMAN; IN VITRO STUDY; NEOPLASM; PATHOLOGY; PROCEDURES;

ANIMALS; BIOREACTORS; CELL BIOLOGY; CELL CULTURE TECHNIQUES; HUMANS; IN VITRO TECHNIQUES; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84906816780     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300492     Document Type: Review

References (165)

1. Cook, D., Brown, D., Alexander, R., March, R. et al., Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat. Rev. Drug Discov. 2014, 13, 419-431.
2. Wilding, J. L., Bodmer, W. F., Cancer cell lines for drug discovery and development. Cancer Res. 2014, 74, 2377-2384.
3. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32, 40-51.
4. Bhattacharjee, Y., Biomedicine. Pharma firms push for sharing of cancer trial data. Science 2012, 338.
5. Arrowsmith, J., Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 2011, 10, 87.
6. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K. et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483, 603-607.
7. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D. et al., Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483, 570-575.
8. Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C. et al., Inconsistency in large pharmacogenomic studies. Nature 2013, 504, 389-393.
9. Egeblad, M., Nakasone, E. S., Werb, Z., Tumors as organs: Complex tissues that interface with the entire organism. Dev. Cell 2010, 18, 884-901.
10. Grainger, D. W., Cell-based drug testing; this world is not flat. Adv. Drug Deliv. Rev. 2014, 69-70, vii-xi.
11. Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., Krek, W., 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69-70, 29-41.
12. Eagle, H., Foley, G. E., Cytotoxicity in human cell cultures as a primary screen for the detection of anti-tumor agents. Cancer Res. 1958, 18, 1017-1025.
13. Hirschberg, E., Tissue culture in cancer chemotherapy screening. Cancer Res. 1958, 18, 869-878.
14. Hamburger, A. W., Salmon, S. E., Primary bioassay of human tumor stem cells. Science 1977, 197, 461-463.
15. Shoemaker, R. H., Wolpert-DeFilippes, M. K., Kern, D. H., Lieber, M. M. et al., Application of a human tumor colony-forming assay to new drug screening. Cancer Res. 1985, 45, 2145-2153.
16. Fiebig, H. H., Maier, A., Burger, A. M., Clonogenic assay with established human tumour xenografts: Correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer (Oxford Engl.) 2004, 40, 802-820.
17. Cortazar, P., Johnson, B. E., Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol. 1999, 17, 1625-1631.
18. Shoemaker, R. H., The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6, 813-823.
19. Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J. et al., The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013, 73, 4372-4382.
20. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J. et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, 431-435.
21. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., Rosen, N., RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464, 427-430.
22. O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D. et al., mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
23. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M. et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500-504.
24. Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E. et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487, 505-509.
25. Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., Nielsen, L. K., Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol. Bioeng. 2003, 83, 173-180.
26. Friedrich, J., Seidel, C., Ebner, R., Kunz-Schughart, L. A., Spheroid-based drug screen: Considerations and practical approach. Nat. Protoc. 2009, 4, 309-324.
27. Lee, J. M., Mhawech-Fauceglia, P., Lee, N., Parsanian, L. C. et al., A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93, 528-542.
28. Vinci, M., Gowan, S., Boxall, F., Patterson, L. et al., Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012, 10, 29.
29. Song, K.-D., Liu, T.-Q., Li, X.-Q., Cui, Z.-F. et al., Three-dimensional expansion: In suspension culture of SD rat's osteoblasts in a rotating wall vessel bioreactor. Biomed. Environ. Sci. 2007, 20, 91-98.
30. Lin, R.-Z., Lin, R.-Z., Chang, H.-Y., Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J. 2008, 3, 1172-1184.
31. Lin, R.-Z., Chou, L.-F., Chien, C.-C. M., Chang, H.-Y., Dynamic analysis of hepatoma spheroid formation: Roles of E-cadherin and beta1-integrin. Cell Tissue Res. 2006, 324, 411-422.
32. Kunz-Schughart, L. A., Multicellular tumor spheroids: Intermediates between monolayer culture and in vivo tumor. Cell Biol. Int. 1999, 23, 157-161.
33. Sutherland, R. M., Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 1988, 240, 177-184.
34. Frankel, A., Buckman, R., Kerbel, R. S., Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997, 57, 2388-2393.
35. Kerr, D. J., Wheldon, T. E., Kerr, A. M., Freshney, R. I., Kaye, S. B., The effect of adriamycin and 4'-deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids. Br. J. Cancer 1986, 54, 423-429.
36. Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J. et al., Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA 1993, 90, 3294-3298.
37. Longati, P., Jia, X., Eimer, J., Wagman, A. et al., 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 2013, 13, 95.
38. Tung, Y.-C., Hsiao, A. Y., Allen, S. G., Torisawa, Y. et al., High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. The Analyst 2011, 136, 473-478.
39. Tunggal, J. K., Cowan, D. S., Shaikh, H., Tannock, I. F., Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 1999, 5, 1583-1586.
40. Wenzel, C., Riefke, B., Gründemann, S., Krebs, A. et al., 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp. Cell Res. 2014, 323, 131-143.
41. Ohmori, T., Yang, J. L., Price, J. O., Arteaga, C. L., Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 1998, 245, 350-359.
42. Green, S. K., Francia, G., Isidoro, C., Kerbel, R. S., Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol. Cancer Ther. 2004, 3, 149-159.
43. Howes, A. L., Chiang, G. G., Lang, E. S., Ho, C. B. et al., The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 2007, 6, 2505-2514.
44. Ihle, N. T., Williams, R., Chow, S., Chew, W. et al., Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 3, 763-772.
45. Koul, D., Shen, R., Kim, Y.-W., Kondo, Y. et al., Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro-Oncology 2010, 12, 559-569.
46. Rodon, J., Dienstmann, R., Serra, V., Tabernero, J., Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013, 10, 143-153.
47. Thoma, C. R., Stroebel, S., Rösch, N., Calpe, B. et al., A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J. Biomol. Screen. 2013, 18, 1330-1337.
48. Gottfried, E., Kunz-Schughart, L. A., Andreesen, R., Kreutz, M., Brave little world: Spheroids as an in vitro model to study tumor-immune-cell interactions. Cell Cycle (Georgetown Tex.) 2006, 5, 691-695.
49. Hauptmann, S., Zwadlo-Klarwasser, G., Jansen, M., Klosterhalfen, B., Kirkpatrick, C. J., Macrophages and multicellular tumor spheroids in co-culture: A three-dimensional model to study tumor-host interactions. Evidence for macrophage-mediated tumor cell proliferation and migration. Am. J. Pathol. 1993, 143, 1406-1415.
50. Kunz-Schughart, L. A., Schroeder, J. A., Wondrak, M., van Rey, F. et al., Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro. Am. J. Physiol. Cell Physiol. 2006, 290, C1385-C1398.
51. Kunz-Schughart, L. A., Heyder, P., Schroeder, J., Knuechel, R., A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp. Cell Res. 2001, 266, 74-86.
52. Seidl, P., Huettinger, R., Knuechel, R., Kunz-Schughart, L. A., Three-dimensional fibroblast-tumor cell interaction causes downregulation of RACK1 mRNA expression in breast cancer cells in vitro. Int. J. Cancer 2002, 102, 129-136.
53. Brouty-Boyé, D., Magnien, V., Myofibroblast and concurrent ED-B fibronectin phenotype in human stromal cells cultured from non-malignant and malignant breast tissue. Eur. J. Cancer (Oxford Engl.) 1990 1994, 30A, 66-73.
54. Costa, E. C., Gaspar, V. M., Coutinho, P., Correia, I. J., Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models. Biotechnol. Bioeng. 2014, 111, 1672-1685.
55. Amann, A., Zwierzina, M., Gamerith, G., Bitsche, M. et al., Development of an innovative 3D cell culture system to study tumour-stroma interactions in non-small cell lung cancer cells. PLoS ONE 2014, 9, e92511.
56. Härmä, V., Virtanen, J., Mäkelä, R., Happonen, A. et al., A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 2010, 5, e10431.
57. Correia, A. L., Bissell, M. J., The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 2012, 15, 39-49.
58. Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C. et al., Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5, 662-668.
59. Aoudjit, F., Vuori, K., Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20, 4995-5004.
60. Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R. et al., β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011, 13, R84.
61. Menendez, J. A., Vellon, L., Mehmi, I., Teng, P. K. et al., A novel CYR61-triggered "CYR61-alphavbeta3 integrin loop" regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005, 24, 761-779.
62. Danen, E. H. J., Integrin signaling as a cancer drug target. ISRN Cell Biol. 2013, 2013, 1-14.
63. McBeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K., Chen, C. S., Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell 2004, 6, 483-495.
64. Park, J. S., Chu, J. S., Tsou, A. D., Diop, R. et al., The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-β. Biomaterials 2011, 32, 3921-3930.
65. Levental, K. R., Yu, H., Kass, L., Lakins, J. N. et al., Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139, 891-906.
66. Pathak, A., Kumar, S., Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl. Acad. Sci. USA 2012, 109, 10334-10339.
67. Soman, P., Kelber, J. A., Lee, J. W., Wright, T. N. et al., Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. Biomaterials 2012, 33, 7064-7070.
68. Schrader, J., Gordon-Walker, T. T., Aucott, R. L., van Deemter, M. et al., Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology (Baltimore Md.) 2011, 53, 1192-1205.
69. Zustiak, S., Nossal, R., Sackett, D. L., Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs. Biotechnol. Bioeng. 2014, 111, 396-403.
70. Orkin, R. W., Gehron, P., McGoodwin, E. B., Martin, G. R. et al., A murine tumor producing a matrix of basement membrane. J. Exp. Med. 1977, 145, 204-220.
71. Hughes, C. S., Postovit, L. M., Lajoie, G. A., Matrigel: A complex protein mixture required for optimal growth of cell culture. Proteomics 2010, 10, 1886-1890.
72. Emerman, J. T., Enami, J., Pitelka, D. R., Nandi, S., Hormonal effects on intracellular and secreted casein in cultures of mouse mammary epithelial cells on floating collagen membranes. Proc. Natl. Acad. Sci. USA 1977, 74, 4466-4470.
73. Emerman, J. T., Pitelka, D. R., Maintenance and induction of morphological differentiation in dissociated mammary epithelium on floating collagen membranes. In Vitro 1977, 13, 316-328.
74. Barcellos-Hoff, M. H., Aggeler, J., Ram, T. G., Bissell, M. J., Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Dev. (Cambridge England) 1989, 105, 223-235.
75. Petersen, O. W., Rønnov-Jessen, L., Howlett, A. R., Bissell, M. J., Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. USA 1992, 89, 9064-9068.
76. Fournier, M. V., Martin, K. J., Kenny, P. A., Xhaja, K. et al., Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 2006, 66, 7095-7102.
77. Martin, K. J., Patrick, D. R., Bissell, M. J., Fournier, M. V., Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008, 3, e2994.
78. Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M. et al., The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1, 84-96.
79. Luca, A. C., Mersch, S., Deenen, R., Schmidt, S. et al., Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS ONE 2013, 8, e59689.
80. Cichon, M. A., Gainullin, V. G., Zhang, Y., Radisky, D. C., Growth of lung cancer cells in three-dimensional microenvironments reveals key features of tumor malignancy. Integr. Biol. Quant. Biosci. Nano Macro 2012, 4, 440-448.
81. Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M. et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459, 262-265.
82. Hongisto, V., Jernström, S., Fey, V., Mpindi, J.-P. et al., High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells. PLoS ONE 2013, 8, e77232.
83. Song, C. W., Griffin, R., Park, H. J., Influence of Tumor pH on Therapeutic Response. In: Teicher, B. A. (Ed.), Cancer drug discovery and development: Cancer drug resistance. Humana Press Inc., Totowa NJ 2006, pp. 21-42.
84. Khramtsov, V. V., Gillies, R. J., Janus-faced tumor microenvironment and redox. Antioxid. Redox Signal. 2014, 21, 723-729.
85. Zeng, W., Liu, P., Pan, W., Singh, S. R., Wei, Y., Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2014, in press.
86. Getzenberg, R. H., Coffey, D. S., Changing the energy habitat of the cancer cell in order to impact therapeutic resistance. Mol. Pharm. 2011, 8, 2089-2093.
87. Lim, K.-T., Seonwoo, H., Son, H.-M., Baik, S.-J. et al., Biomechanical effects of fluid dynamics and mass transport on cell growth in perfusion bioreactors for tissue engineering. Tissue Eng. Regen. Med. 2009, 6, 1327-1342.
88. Serra, M., Brito, C., Correia, C., Alves, P. M., Process engineering of human pluripotent stem cells for clinical application. Trends Biotechnol. 2012, 30, 350-359.
89. Plunkett, N., O'Brien, F. J., Bioreactors in tissue engineering. Technol. Health Care 2011, 19, 55-69.
90. Placzek, M. R., Chung, I.-M., Macedo, H. M., Ismail, S. et al., Stem cell bioprocessing: Fundamentals and principles. J. R. Soc. Interface 2009, 6, 209-232.
91. Jaeger, A. A., Das, C. K., Morgan, N. Y., Pursley, R. H. et al., Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials 2013, 34, 8301-8313.
92. Stratmann, A. T., Fecher, D., Wangorsch, G., Göttlich, C. et al., Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol. Oncol. 2014, 8, 351-365.
93. Alessandri, K., Sarangi, B. R., Gurchenkov, V. V., Sinha, B. et al., Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro. Proc. Natl. Acad. Sci. USA 2013, 110, 14843-14848.
94. Panchalingam, K. M., Paramchuk, W. J., Chiang, C.-Y. K., Shah, N. et al., Bioprocessing of human glioblastoma brain cancer tissue. Tissue Eng. A 2010, 16, 1169-1177.
95. Youn, B. S., Sen, A., Behie, L. A., Girgis-Gabardo, A., Hassell, J. A., Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol. Prog. 2006, 22, 801-810.
96. Serra, M., Brito, C., Costa, E. M., Sousa, M. F. Q., Alves, P. M., Integrating human stem cell expansion and neuronal differentiation in bioreactors. BMC Biotechnol. 2009, 9, 82.
97. Tang, Y.-J., Li, H.-M., Hamel, J.-F. P., Effects of dissolved oxygen tension and agitation rate on the production of heat-shock protein glycoprotein 96 by MethA tumor cell suspension culture in stirred-tank bioreactors. Bioprocess Biosyst. Eng. 2008, 32, 475-484.
98. Rodday, B., Hirschhaeuser, F., Walenta, S., Mueller-Klieser, W., Semiautomatic growth analysis of multicellular tumor spheroids. J. Biomol. Screen. 2011, 16, 1119-1124.
99. Tostões, R. M., Leite, S. B., Serra, M., Jensen, J. et al., Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology (Baltimore Md.) 2012, 55, 1227-1236.
100. Serra, M., Correia, C., Malpique, R., Brito, C. et al., Microencapsulation technology: A powerful tool for integrating expansion and cryopreservation of human embryonic stem cells. PLoS ONE 2011, 6, e23212.
101. Brito, C., Simão, D., Costa, I., Malpique, R. et al., 3D cultures of human neural progenitor cells: Dopaminergic differentiation and genetic modification [corrected]. Methods (San Diego Calif.) 2012, 56, 452-460.
102. Rasey, J. S., Cornwell, M. M., Maurer, B. J., Boyles, D. J. et al., Growth and radiation response of cells grown in macroporous gelatin microcarriers (CultiSpher-G). Br. J. Cancer. Suppl. 1996, 27, S78-S81.
103. Hirschhaeuser, F., Walenta, S., Mueller-Klieser, W., Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol. Immunother. CII 2010, 59, 1675-1684.
104. Hirschhaeuser, F., Leidig, T., Rodday, B., Lindemann, C., Mueller-Klieser, W., Test system for trifunctional antibodies in 3D MCTS culture. J. Biomol. Screen. 2009, 14, 980-990.
105. Tostões, R. M., Leite, S. B., Miranda, J. P., Sousa, M. et al., Perfusion of 3D encapsulated hepatocytes - a synergistic effect enhancing long-term functionality in bioreactors. Biotechnol. Bioeng. 2011, 108, 41-49.
106. Leite, S. B., Wilk-Zasadna, I., Zaldivar, J. M., Airola, E. et al., Three-dimensional HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 2012, 130, 106-116.
107. Hammond, T. G., Hammond, J. M., Optimized suspension culture: The rotating-wall vessel. Am. J. Physiol.-Renal Physiol. 2001, 281, F12-F25.
108. Goodwin, T. J., Jessup, J. M., Wolf, D. A., Morphologic differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating-wall vessels. Vitro Cell. Dev. Biol. 1992, 28A, 47-60.
109. Jessup, J. M., Goodwin, T. J., Spaulding, G., Prospects for use of microgravity-based bioreactors to study three-dimensional host-tumor interactions in human neoplasia. J. Cell. Biochem. 1993, 51, 290-300.
110. Becker, J. L., Prewett, T. L., Spaulding, G. F., Goodwin, T. J., Three-dimensional growth and differentiation of ovarian tumor cell line in high aspect rotating-wall vessel: Morphologic and embryologic considerations. J. Cell. Biochem. 1993, 51, 283-289.
111. Barrila, J., Radtke, A. L., Crabbé, A., Sarker, S. F. et al., Organotypic 3D cell culture models: Using the rotating wall vessel to study host-pathogen interactions. Nat. Rev. Microbiol. 2010, 8, 791-801.
112. Becker, J. L., Souza, G. R., Using space-based investigations to inform cancer research on Earth. Nat. Rev. Cancer 2013, 13, 315-327.
113. Rhee, H. W., Zhau, H. E., Pathak, S., Multani, A. S. et al., Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell. Dev. Biol. Anim. 2001, 37, 127-140.
114. Wang, R., Xu, J., Juliette, L., Castilleja, A. et al., Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Semin. Cancer Biol. 2005, 15, 353-364.
115. Ma, X., Pietsch, J., Wehland, M., Schulz, H. et al., Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space. FASEB J. 2014, 28, 813-835.
116. Tsui, J. H., Lee, W., Pun, S. H., Kim, J., Kim, D.-H., Microfluidics-assisted in vitro drug screening and carrier production. Adv. Drug Deliv. Rev. 2013, 65, 1575-1588.
117. Yum, K., Hong, S. G., Healy, K. E., Lee, L. P., Physiologically relevant organs on chips. Biotechnol. J. 2014, 9, 16-27.
118. Das, T., Chakraborty, S., Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research? Biomicrofluidics 2013, 7, 11811.
119. Ma, H., Xu, H., Qin, J., Biomimetic tumor microenvironment on a microfluidic platform. Biomicrofluidics 2013, 7, 11501.
120. Håkanson, M., Cukierman, E., Charnley, M., Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv. Drug Deliv. Rev. 2014, 69-70, 52-66.
121. Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C. et al., A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials 2014, 35, 2454-2461.
122. Markov, D. A., Lu, J. Q., Samson, P. C., Wikswo, J. P., McCawley, L. J., Thick-tissue bioreactor as a platform for long-term organotypic culture and drug delivery. Lab Chip 2012, 12, 4560-4568.
123. Zhang, W., Lee, W. Y., Siegel, D. S., Tolias, P., Zilberberg, J., Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng. C Methods 2014, 20, 663-670.
124. Junttila, M. R., de Sauvage, F. J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501, 346-354.
125. Masters, J. R., Human cancer cell lines: Fact and fantasy. Nat. Rev. Mol. Cell Biol. 2000, 1, 233-236.
126. Warburg, O., Versuche an überlebendem Karzinomgewebe. Biochem. Ztg. 1923, 142, 317-333.
127. Warburg, O., Negelein, E., Posener, K., Versuche an Überlebendem Carcinomgewebe. Klin. Wochenschr. 1924, 3, 1062-1064.
128. Kredel, F. E., Tissue culture of intracranial tumors with a note on the meningiomas. Am. J. Pathol. 1928, 4, 337-3403.
129. Wright, J. C., Cobb, J. P., Gumport, S. L., Safadi, D. et al., Further investigation of the relation between the clinical and tissue culture response to chemotherapeutic agents on human cancer. Cancer 1962, 15, 284-293.
130. Hurley, J. D., Yount, L. J., Selection of anticancer drug for palliation using tissue culture sensitivity studies. Am. J. Surg. 1965, 109, 39-42.
131. Röller, M. R., Owen, S. P., Heidelberger, C., Studies on the organ culture of human tumors. Cancer Res. 1966, 26, 626-637.
132. Gey, G. O., Coffman, W. D., Kubicek, M. T., Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res. 1952, 12, 264-265.
133. Krumdieck, C. L., dos Santos, J. E., Ho, K. J., A new instrument for the rapid preparation of tissue slices. Anal. Biochem. 1980, 104, 118-123.
134. Mira-y-Lopez, R., Ossowski, L., Preservation of steroid hormone receptors in organ cultures of human breast carcinomas. Cancer Res. 1990, 50, 78-83.
135. van der Kuip, H., Mürdter, T. E., Sonnenberg, M., McClellan, M. et al., Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006, 6, 86.
136. Holliday, D. L., Moss, M. A., Pollock, S., Lane, S. et al., The practicalities of using tissue slices as preclinical organotypic breast cancer models. J. Clin. Pathol. 2013, 66, 253-255.
137. Milani, C., Welsh, J., Katayama, M. L. H., Lyra, E. C. et al., Human breast tumor slices: A model for identification of vitamin D regulated genes in the tumor microenvironment. J. Steroid Biochem. Mol. Biol. 2010, 121, 151-155.
138. Sonnenberg, M., van der Kuip, H., Haubeis, S., Fritz, P. et al., Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008, 8, 364.
139. Séveno, C., Loussouarn, D., Bréchet, S., Campone, M. et al., γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res. 2012, 14, R96.
140. Vaira, V., Fedele, G., Pyne, S., Fasoli, E. et al., Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 2010, 107, 8352-8356.
141. Dong, M., Philippi, C., Loretz, B., Nafee, N. et al., Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA. Int. J. Pharm. 2011, 419, 33-42.
142. Schmid, J. O., Dong, M., Haubeiss, S., Friedel, G. et al., Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin. Cancer Res. 2012, 72, 5824-5832.
143. Liu, Y., Lang, F., Xie, X., Prabhu, S. et al., Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011, 2, e121.
144. Merz, F., Müller, M., Taucher-Scholz, G., Rödel, F. et al., Tissue slice cultures from humans or rodents: A new tool to evaluate biological effects of heavy ions. Radiat. Environ. Biophys. 2010, 49, 457-462.
145. Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H. et al., Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br. J. Cancer 2013, 109, 2685-2695.
146. Estes, J. M., Oliver, P. G., Straughn, J. M. Jr., Zhou, T. et al., Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol. Oncol. 2007, 105, 291-298.
147. Kendrick, J. E., Straughn, J. M. Jr., Oliver, P. G., Wang, W. et al., Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol. Oncol. 2008, 108, 591-597.
148. Weissinger, D., Tagscherer, K. E., Macher-Göppinger, S., Haferkamp, A. et al., The soluble decoy receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Mol. Cancer 2013, 12, 120.
149. Kiviharju-af Hällström, T. M., Jäämaa, S., Mönkkönen, M., Peltonen, K. et al., Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. USA 2007, 104, 7211-7216.
150. Kern, M. A., Haugg, A. M., Eiteneuer, E., Konze, E. et al., Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: Effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver Int. 2006, 26, 604-612.
151. Frederick, P. J., Kendrick, J. E., Straughn, J. M. Jr., Della Manna, D. L. et al., Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int. J. Gynecol. Cancer 2009, 19, 814-819.
152. Grosso, S. H. G., Katayama, M. L. H., Roela, R. A., Nonogaki, S. et al., Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res. 2013, 352, 671-684.
153. Gerlach, M. M., Merz, F., Wichmann, G., Kubick, C. et al., Slice cultures from head and neck squamous cell carcinoma: A novel test system for drug susceptibility and mechanisms of resistance. Br. J. Cancer 2014, 110, 479-488.
154. Merz, F., Gaunitz, F., Dehghani, F., Renner, C. et al., Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro-Oncology 2013, 15, 670-681.
155. Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C. et al., Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 2012, 122, 899-910.
156. Kirby, T. O., Rivera, A., Rein, D., Wang, M. et al., A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin. Cancer Res. 2004, 10, 8697-8703.
157. Stoff-Khalili, M. A., Stoff, A., Rivera, A. A., Mathis, J. M. et al., Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol. Ther. 2005, 4, 1203-1210.
158. Zimmermann, M., Armeanu, S., Smirnow, I., Kupka, S. et al., Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int. J. Oncol. 2009, 34, 1247-1256.
159. Van Geer, M.-A., Kuhlmann, K. F. D., Bakker, C. T., ten Kate, F. J. W. et al., Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J. Gastroenterol. 2009, 15, 1359-1366.
160. Pennington, K., Chu, Q. D., Curiel, D. T., Li, B. D. L., Mathis, J. M., The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J. Surg. Res. 2010, 163, 270-275.
161. Fisher, R. L., Vickers, A. E. M., Preparation and culture of precision-cut organ slices from human and animal. Xenobiotica 2013, 43, 8-14.
162. Swanton, C., Intratumor heterogeneity: Evolution through space and time. Cancer Res. 2012, 72, 4875-4882.
163. Zimmermann, M., Lampe, J., Lange, S., Smirnow, I. et al., Improved reproducibility in preparing precision-cut liver tissue slices. Cytotechnology 2009, 61, 145-152.
164. Young, M., Zimmer, S., Whitmore, A., Drug molecules and biology: Network and systems aspects. In: Morphy, R., Harris, C. J. (Eds.), Designing multi-target drugs. Royal Society of Chemistry, Cambridge, UK 2012, pp. 32-49.
165. Huijbers, I. J., Bin Ali, R., Pritchard, C., Cozijnsen, M. et al., Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 2014, 6, 212-225.